Concepedia

Melissa H.S. Hillebrandt-Roeffen

MH

14

Publications

497

Citations

13

H-Index

2014

Active since

Affiliations

Radboud University Medical Center(Current)

Radboud University Nijmegen

Royal Marsden NHS Foundation Trust

Institute of Cancer Research

The Netherlands Cancer Institute

Melissa H.S. Hillebrandt-Roeffen is an author at Radboud University Medical Center specializing in tumor biology, medicine, and oncology.

Top concepts

Publications per year

2014–2022

14

Publications

14

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent

Anke van Erp, Yvonne M.H. Versleijen‐Jonkers, Melissa H.S. Hillebrandt-Roeffen et al. · Oncotarget · 2017 · 95 citations · Full text

Next generation sequencing in synovial sarcoma reveals novel gene mutations

Myrella Vlenterie, Melissa H.S. Hillebrandt-Roeffen, Uta Flucke et al. · Oncotarget · 2015 · 63 citations · Full text

The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma

Emmy D.G. Fleuren, Melissa H.S. Hillebrandt-Roeffen, Uta Flucke et al. · Oncotarget · 2014 · 47 citations · Full text

DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas

Marije E. Weidema, Ellen van de Geer, Christian Koelsche et al. · Clinical Cancer Research · 2019 · 41 citations

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib

Anke van Erp, Melissa H.S. Hillebrandt-Roeffen, Laurens van Houdt et al. · Targeted Oncology · 2017 · 39 citations · Full text

Rows per page

1–5 of 14